Caris Life Sciences (CAI) Cash from Investing Activities (2024 - 2026)

Caris Life Sciences' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$10.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 284.6% year-over-year to -$10.3 million; the TTM figure through Mar 2026 stood at -$23.9 million (changed N/A YoY), while the FY2025 annual figure was -$16.3 million, down 130.72% from the prior year.
• Cash from Investing Activities was -$10.3 million for Q1 2026 at Caris Life Sciences, down from -$5.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$1.4 million in Q2 2025 to a low of -$10.3 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$4.4 million across 3 years, with a median of -$2.7 million in 2025.
• Biggest YoY gain for Cash from Investing Activities was 122.27% in 2025; the steepest drop was 288.13% in 2025.
• A 3-year view of Cash from Investing Activities shows it stood at -$2.3 million in 2024, then slumped by 122.27% to -$5.1 million in 2025, then slumped by 103.18% to -$10.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$10.3 million (Q1 2026), -$5.1 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.